Market Place
Sourcing Support
All News #Library
Biotech
Brii Bio Presents Post-Treatment Hbsag Rebound Analysis At APASL
26 Apr 2026 //
FIRSTWORD PHARMA
Brii Bio Unveils Corporate Updates, 2025 Financial Result
19 Mar 2026 //
PR NEWSWIRE
Brii Biosciences Unveils Phase 2 ENSURE Study Data At AASLD
10 Nov 2025 //
PR NEWSWIRE
Brii Bio Reveals Phase 2 ENSURE Study Results In Nature Medicine
07 Nov 2025 //
PR NEWSWIRE
Brii Bioscience Issues Corporate Updates and Interim 2025 Results
21 Aug 2025 //
PR NEWSWIRE
Brii Licenses BRII-693 Rights in Greater China to Joincare Group
03 Jul 2025 //
PR NEWSWIRE
Brii Bio Presents Phase 2 ENSURE Study Data at EASL Congress 2025
07 May 2025 //
PR NEWSWIRE
Brii Bio Reveals New Data from Phase 2 ENSURE Study at APASL 2025
30 Mar 2025 //
PR NEWSWIRE
Brii Biosciences Updates on Full-Year 2024 Financial Results
21 Mar 2025 //
PR NEWSWIRE
Brii Bio Acquires BRII-179 IP Rights, Completes Study Enrollment
31 Dec 2024 //
PR NEWSWIRE
Brii Bio Compares siRNA and PEG-IFN? Combo for HBV at AASLD 2024
19 Nov 2024 //
PR NEWSWIRE
VBI Vaccines shrinks `long-term burn` with $33M Brii Bio deal
14 Feb 2024 //
FIERCE PHARMA
Brii Biosciences Announces Agreement to Acquire VBI`s IP Rights in BRII-179
13 Feb 2024 //
PR NEWSWIRE
VBI Vaccines Partner Brii Announces Results of Phase 2 Study Evaluating BRII-179
06 Sep 2023 //
BUSINESSWIRE
Brii pays VBI $15M for global rights to hepB program and more
06 Jul 2023 //
FIERCE BIOTECH
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio
05 Jul 2023 //
PR NEWSWIRE
Brii Bio Announces New Data from Partners for HBV Functional Cure at EASL
25 Jun 2023 //
PR NEWSWIRE
Brii Bio Announces Agreements with Qpex & Acquiring Global Rights for BRII-693
25 Jun 2023 //
PR NEWSWIRE
Brii Biosciences halts manufacture of COVID-19 antibody combo
25 Mar 2023 //
FIERCE PHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.